Jan 18 2021 Read 353 Times
CN Bio has announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung disease, often occurring following SARS-CoV-2 infection. Subsequently, the University will investigate anti-inflammatory, anti-fibrotic and anti-viral agents to treat patients.
For patients suffering from the chronic complications of COVID-19, many long-term health effects have been identified, including respiratory complications resulting from interstitial lung disease. Through the collaboration, CN Bio’s Sydney-based distributor, AXT, will provide the University of Melbourne access to the Company’s proprietary PhysioMimix™ Organ-on-Chip system, to create a more human-relevant COVID-infected lung culture than current
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
Industry News: CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
16 Dec 2020
CN Bio has announced a collaboration with the University of Melbourne focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodeling seen in chronic interstitial lung disease, often occurring following SARS-CoV-2 infection. Subsequently, the University will investigate anti-inflammatory, anti-fibrotic and anti-viral agents to treat patients.
CN Bio, University of Melbourne collaborate to advance therapies for respiratory complications in recovered Covid-19 patients pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
(1)
CN Bio s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection
CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung disease, often occurring following SARS-CoV-2 infection. Subsequently, the University will investigate anti-inflammatory, anti-fibrotic and anti-viral agents to treat patients.